that mutations in the coding region of ROX are uncommon in human breast tumorigenesis. ᭧ 1998 Academic Press We have recently isolated a human gene, ROX, encoding a new member of the basic helix-loop-helix leucine zipper protein family. ROX is capable of heterodimerizing with Max and acts as a transcriptional re-INTRODUCTION pressor in an E-box-driven reporter gene system, while it was found to activate transcription in HeLa cells.
The ROX cDNA was radioactively labeled using [ 32 P]dCTP and
We have recently described a new member of the probed to the digested cosmid filter. Prehybridization and hybridizaMax-interacting protein family (ROX), which contains tion were performed in Rapid-Hyb buffer (Amersham) at 65ЊC, aca bHLHZip and binds DNA at the E-box (CANNTG) cording to the supplier's instructions. The ROX cDNA hybridized to consensus by forming heterodimers with Max (Meroni two EcoRI fragments of 5.5 and 8.5 kb. A mini-library of each of these fragments was generated by digesting 200 ng of DNA from the et al., 1997). The same protein was independently depurified fragments with 5 U of Sau3AI and subcloning in a pBluescribed by others and termed Mnt (Hurlin et al., 1997) .
script II KS(/) vector (Stratagene, La Jolla, CA) at the BamHI site.
Transcriptional studies in yeast and mammalian cells Ligation and transformation in competent DH5a
Escherichia coli indicated that ROX represses transcription through in-were performed as described (Sambrook et al., 1989) . Positive clones teraction between its N-terminus and the mSin3 core-were identified by colony hybridization using the ROX cDNA as probe. Plasmid DNA was prepared according to standard procedures pressor, while it activates transcription in HeLa cells. (Sambrook et al., 1989) and sequenced on an ABI 377 automated ROX expression is ubiquitous in various tissues and DNA sequencer (Perkin-Elmer-ABI), using M13 forward and recell lines, but is tightly regulated during cell growth, verse primers. with ROX mRNA being up-regulated 2 h after induccDNA and genomic sequences were compared and assembled using tion with TPA and returning to basal levels as early as AutoAssember software (PE Applied Biosystem, version 1.4). 4 h after induction (Hurlin et al., 1997; Meroni et al., Collection of breast tumor samples and control population. Sixteen paired primary breast tumors and normal tissue samples were 1997).
obtained from patients at the S. Giovanni Vecchio Hospital in Turin
The apparent role of Mad proteins in cell prolifera- (Italy) .
tion and differentiation has led several authors to in-DNA from peripheral blood and tumor tissue was prepared acvestigate the role of these proteins in human cancer. cording to standard procedures (Sambrook et al., 1989) . Merlo et al. (1994) .
ing loss of heterozygosity (LOH) in human malignan-Detection of LOH by PCR using cCI17-713 was performed as decies. For instance, MXI1 maps to 10q21-q25 (Edelhoff scribed (Stack et al., 1995) . D17S379 is a dinucleotide repeat conet al., 1994) and MAX maps to 14q22-q24 (Wagner et tained in the 3 untranslated region of the ROX gene and has already been reported (Carrozzo and Ledbetter, 1993) . The samples were also al., 1992), two chromosomal regions deleted in prostate tested for LOH at the BRCA1 locus, using the polymorphic marker cancer (Lundgren et al., 1992) and in B-cell chronic D17S855 (Dib et al., 1996) . One hundred nanograms of genomic DNA lymphocytic leukemia (Wagner et al., 1992) , respec-was used in each PCR. Detection of LOH was performed running tively. The finding of intragenic mutations in the MXI1 tumor/normal PCR products in adjacent gel tracks and visually comgene, reported in primary prostate tumors with 10q24-paring relative allele intensities. q25 deletions (Eagle et al., 1995) , is consistent with a SSCP analysis in sporadic breast tumors. Exons I-VI of the ROX gene were screened for the presence of mutations in the open reading ''two-hit'' event, leading to a loss of function involving frame (ORF) of the gene. Oligonucleotide primers were designed to both of the alleles of a tumor suppressor gene in neoamplify fragments of ORF no longer than 400 bp. plastic cells.
Each fragment was amplified from 100 ng of genomic DNA as Interestingly, ROX maps to 17p13.3, a region that template in a final reaction volume of 25 ml, containing 0.25 mM shows LOH in several human neoplasias, including concentrations of each dNTP, 0.5 mM concentrations of each primer, and 1.25 U of Taq polymerase (Perkin-Elmer-ABI, Foster City, CA) breast cancer (Devilee et al., 1989; Mackay et al., 1988) , in standard PCR buffer (10 mM pH 8.3, 50 mM KCl, 1.5 bladder carcinoma (Williamson et al., 1994) , medulmM MgCl 2 , and 0.01% gelatin). Reactions were performed in a PE480 loblastoma (McDonald et al., 1994) , neuroectodermal thermal cycler (Perkin-Elmer) with an initial denaturation at 95ЊC cancer (Biegel et al., 1992) , and osteosarcoma (Andreas-for 2 min, followed by 35 cycles at 95ЊC for 1 min, annealing for 1 sen et al., 1993) . min and extension at 72ЊC for 1 min. Primer sequences, annealing temperatures, and sizes of amplified products are listed in Table 3 .
The transcriptional properties of ROX, its down-reg-SSCP analysis was carried out using a previously described nonraulation in proliferating cells, and its chromosomal mapdioactive method (Lo Nigro et al., 1997). ping to a region undergoing LOH in a number of maligShifted amplification products were sampled directly from SSCP nancies prompted us to search for inactivating muta-minigel, processed as described, and subjected to 25 additional PCR tions of the ROX gene in primary breast cancers, cycles.
Reamplified products were subcloned into pBluescript II KS(/) at showing LOH at 17p13.3.
the EcoRV site and analyzed on an ABI 377 automated DNA sequencer (Perkin-Elmer-ABI), using fluorescently labeled M13 for-
MATERIALS AND METHODS
ward and reverse oligonucleotide primers.
Each time a band-shift was seen, amplification of the same fragment and SSCP analysis were performed, under the above-reported Characterization of the ROX gene structure. ROX genomic clones conditions, using DNA from peripheral leukocytes as template. c197-2, c197-4, and c197-9 have been previously described (Ledbetter Direct sequencing of the PCR products was performed on an et al., 1992) . The comparison of the restriction pattern detected on ABI377 automated DNA sequencer (Perkin-Elmer-ABI) using Dye human genomic DNA and cosmid c197-4 demonstrated that this cosTerminator Chemistry (Prism DyeDeoxy Terminator, Cycle Sequencmid contains the entire ROX gene.
ing Kit, Perkin-Elmer-ABI). One microgram of DNA from c197-4 was digested with 10 units of Confirmation of polymorphisms in the control population. PolyEcoRI (Boehringer Mannheim), separated across a 0.8% agarose, 11 morphisms G325A, C350A, and C505T were confirmed using a re-TAE gel, and transferred to Hybond-N / membrane (Amersham, Arlington Heights, IL).
striction assay based on restriction polymorphisms created by the base difference. The T1335C change was confirmed by direct sequenc-
The ROX gene consists of six exons, the sizes of which ing as already described.
are reported in Fig. 1 . Rapid amplification of cDNA PCR amplification was performed using as template 100 ng of ends (RACE) and RNase protection assays that were genomic DNA in a final reaction volume of 25 ml. PCR were carried performed to map the cap site have so far been unsucout as described above. Amplified products were digested using 5 U of the informative restriction enzyme, according to the manufacturer's cessful. Preliminary primer extension data indicate guidelines (Table 4) , and the digested products were separated across that multiple start sites are utilized (data not shown).
a 2% STG agarose / 2% NuSieve agarose (FMC Bioproducts, Rock-
The intron-exon boundaries were identified, and the land, ME), 11 TAE gel.
donor and acceptor splice sites at each junction conform Amplification products obtained with primers ExA1aup -to the consensus (Table 1 ). The size of most introns
ExA1alow (see Table 3 for primer sequences) were digested with
KspI; alleles carrying a G in position 325 showed two fragments of could be estimated from PCR amplification of genomic 67 and 82 bp, while alleles with an A resulted in an uncut fragment templates by employing exonic primers.
of 149 bp. The C350A change causes the suppression of an HhaI site, so that the digested PCR products, obtained using primers
Loss of Heterozygosity at 17p13.3 and Mutation
ExA1aup-ExA1alow, showed two bands (117 and 32 bp) instead of three (92, 25, and 32 bp). The C505T change was investigated using
Analysis in Sporadic Breast Cancer
primers ExA1blow and 738mut (5CAGCCCAGCCACTGCCCCTGG-CGCCACGTC-3). The last primer was designed by inserting two DNA from 16 sporadic breast carcinomas was inimismatches to abolish two MnlI sites and make unique the retially analyzed for loss of heterozygosity at 17p13.3. maining polymorphic MnlI site. Alleles with a C in position 505 LOH was assessed by genotyping the samples with an showed, after digestion, two fragments (175 and 32 bp), while PCR STR located within the 3 untranslated region of the products from the alleles with a T were not cut (207 bp).
ROX gene (D17S379) (Carrozzo and Ledbetter, 1993) .
EMSA. The mutation found in the ROX polymorphisms were recreated by Quick-change (Stratagene) according to the manufacturer's Two additional polymorphic markers, cCI17-713 instructions. ROX WT, A109T, A117E, and L169F were expressed (D17S559), mapping proximal to ROX, and pYNZ22 in vitro and tested for their ability to bind DNA essentially as de-(D17S5), mapping about 300 kb distal to it, were emscribed by Meroni et al. (1997) . The amounts of produced proteins ployed. A subset of these data are reported elsewhere were assessed by SDS-PAGE, and equal amounts were used to perform the EMSAs. (Stack et al., 1995) . The results are shown in Table 2 .
LOH was detected in nine tumors at the D17S379 Samples showing LOH were further analyzed to with three cycles of freeze-thawing. Luciferase activity was mea-search for subtle mutations in the nondeleted allele. sured using a luminometer (Lumat LB9501).
Primers for single-strand conformation polymorphism (SSCP) analysis were designed to amplify coding frag-RESULTS ments from each of the exons (Table 3) .
Two electrophoretic migration band-shifts were seen Gene Structure and Genomic Organization of the in samples 514 and 572, involving exons II and VI, Human ROX Gene respectively. The shifted single-stranded fragments were isolated, reamplified, subcloned, and sequenced The structure of the human ROX gene was determined by comparison between the cDNA sequence and on both strands. The following nucleotide changes were found: a dC r dA transversion at position 562 in sample the corresponding genomic sequence (GenBank Accession Nos. X96401 and Y13440-Y13444, respectively). 514, leading to an A117E substitution; and a dC r dT transition at nucleotide 1811 in sample 572 in the third The entire gene appears to be contained in a single cosmid (c197-4), thus spanning a genomic region position at codon 533, resulting in a synonymous nucleotide change. smaller than 40 kb. To investigate whether the change found in the tu-(A445A). In addition, the A117E substitution found in patient 514 was detected in 10% of the control alleles. mor tissue was due to a de novo event, exons II and VI were amplified from the peripheral blood DNA of The allele frequency for each polymorphism and the method used for confirmation of the nucleotide change patients 514 and 572, and the PCR products were directly sequenced. Each patient was shown to carry the are reported in Table 4 .
The C1811T transition found in patient 572 was not nucleotide change in the heterozygous state.
A search for polymorphisms in the ROX gene was detected in any of the control alleles. performed by SSCP analysis on 25 unrelated individu-DNA-Binding Activity and Transcriptional Properties als. Four nucleotide polymorphisms were identified: a of ROX Variants 537(G r A) transition in exon II, leading to a A109T substitution; a 717(C r T) transition in exon II, leading
To assess the functional consequences of the variato a L169F substitution; and a 1547(T r C) transition tions found in the ROX polymorphisms A109T, A117E, in exon VI, leading to a synonymous nucleotide change and L169F, we reproduced the same mutations in the ROX cDNA. Each mutant protein was tested for DNA the Li-Fraumeni syndrome (Malkin, 1993) . a For exon III, the presence of a short tandem repeat in the intron sequence flanking the splice donor necessitated the digestion of the PCR product with the restriction enzyme MboII. SSCP analysis was performed on the 79-bp exonic digestion product.
b The shift was confirmed in patient 572 using primers ExE5up-ExE5low, since the nucleotide change lies in the region of overlap between the two PCR fragments.
Point mutations in a tumor suppressor gene and data suggest that loss of Mxi1 protein function occurs as a result of deletion of one allele in association with LOH in the same locus have been demonstrated to occur in a number of malignancies. Mutations in the re-point mutations in the retained allele (Eagle et al., 1995) . tained alleles of the MXI1 gene in four primary prostate tumors with 10q24-q25 deletions have been reported This model is also useful for describing familial cancer syndromes, in which the pattern of inheritance is by Eagle et al. (1995) , who described two inactivating mutations (a nucleotide deletion and a splice donor mu-dominant, but the mechanism of tumorigenesis is retation) and two identical missense mutations. These cessive. In these cases, one altered copy of the responsible gene is inherited from a carrier parent, but the tumors have lost the remaining copy (the wildtype) in cancer (Devilee et al., 1989; Mackay et al., 1988) , but -1993) . Detailed mapping and loss of heterozygosity analysis provided evidence for the presence of two inde-ovarian cancer gene BRCA1 has been reported in sporadic breast cancers (Thompson et al., 1995) , but no pendent loci involved in tumorigenesis within 17p13.3, one in the vicinity of D17S5 and the other close to the point mutations have been found in 32 cases of sporadic human breast tumors, all of which show LOH at the telomere (Merlo et al., 1994; Stack et al., 1995) .
The functional data and the chromosomal mapping BRCA1 gene (Futreal et al., 1994) . We have found five nucleotide polymorphisms in the of ROX to chromosome 17p13.3 (about 300 kb proximal to D17S5) make it a good candidate for involvement in ROX gene, three of which are actually amino acid substitutions. ROX variants did not show differences in human neoplasia (Hurlin et al., 1997; Meroni et al., 1997) . Transcriptional studies indicated that ROX re-their ability to bind to the E-box canonical site or in their ability to repress transcription with respect to presses transcription through interaction between the N-terminus of the protein and the mSin3 corepressor, the wildtype protein. However, we cannot exclude the possibility that the amino acid changes might interfere while it activates transcription in HeLa cells. Furthermore, cotransformation assays demonstrated that with the normal function of ROX in vivo, since the function of other putative domains of the protein is still transfection of the ROX expression plasmid with MYC and RAS antagonizes the number of foci generated with unknown.
These data suggest that ROX might not be directly MYC and RAS (Hurlin et al., 1997) .
We have characterized the genomic structure of the involved in tumorigenesis for breast cancer, even though the gene maps to a region undergoing LOH. human ROX gene to analyze all of the exons and their corresponding splice junctions to identify potential in-Alternatively, a different mechanism may result in the loss of gene expression, including alteration in the activating mutations in 16 sporadic breast cancers showing LOH in the ROX region. No mutations were methylation status of the gene. Interestingly, a CpGrich region located at 17p13.3 was previously identified found in this study. A similar result was found in 30 sporadic breast cancers analyzed both for LOH and and was aberrantly hypermethylated in multiple common types of human cancers (Makos et al., 1992 (Makos et al., , 1993a , for inactivating mutations in the human mammaryderived growth inhibitor (MDGI) gene (Phelan et al., 1993b; Pieretti et al., 1995) . These CpG islands were found to be associated with a gene (HIC-1) encoding 1996), whose biological properties and mapping to 1p32-p35, deleted in 21 to 62% of breast cancer sam-for a zinc-finger transcription factor that has been and Prochownik, E. V. (1995) . Mutation of the MXI1 gene in prosshown to suppress growth and viability when transtate cancer. Nat. fected in tumor cells (Makos Wales et al., 1995) . of methylation of its regulatory region requires further Futreal, P., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, investigation to understand the regulation of ROX ex-K., Tavtigian, S., Bennett, L., Haugen-Strano, A., Swensen, J., pression better.
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